For the year ending 2025-12-31, ERNAW had $155K increase in cash & cash equivalents over the period. -$7,054K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Gain on lease termination | 0 |
| Paid-in-kind interest expense | 0 |
| Amortization of debt discount and debt issuance costs | 0 |
| Change in fair value of contingent consideration liability | 0 |
| Deferred revenue | 0 |
| Change in fair value of convertible notes | 0 |
| Fair value adjustments to bridge notes derivative liability | 0 |
| Depreciation and amortization | 65 |
| Stock-based compensation | 1,496 |
| Impairment of right-of-use asset | 33 |
| Loss on disposal of fixed assets | -13 |
| Accrued interest expense | 22 |
| Issuance of common stock in connection with settlement | 69 |
| Issuance of common stock to consultant for services | 141 |
| Other receivables | -342 |
| Prepaid expenses and other current assets | 268 |
| Other non-current assets | -8 |
| Accounts payable and accrued expenses | 60 |
| Operating lease liability | -208 |
| Due from related party | 750 |
| Due to related party | 750 |
| Other liabilities | 15 |
| Net Income Loss | -14,100 |
| Change in fair value of warrant liabilities | -1 |
| Gains Losses On Extinguishment Of Debt | 800 |
| Amortization of right-of-use asset | 198 |
| Forward Sales Contract Expense | -5,800 |
| Net cash used in operating activities | -7,017 |
| Proceeds received from the sale of fixed assets | 0 |
| Purchase of property and equipment | 37 |
| Net cash used in investing activities | -37 |
| Fees paid related to the common stock and prefunded warrant offering | 0 |
| Proceeds received from the convertible notes financing | 0 |
| Fees paid related to the convertible notes financing | 0 |
| Proceeds received from bridge notes financing | 0 |
| Proceeds received from notes payable | 2,250 |
| Proceeds received from issuance of common stock and prefunded warrants | 4,929 |
| Proceeds received from exercise of prefunded warrants | 30 |
| Net cash provided by financing activities | 7,209 |
| Net increase (decrease) in cash | 155 |
| Net increase (decrease) in cash | 155 |
| Cash at beginning of period | 1,729 |
| Cash at end of period | 1,884 |
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)